Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: J Urol. 2020 Jun 18;204(6):1173–1179. doi: 10.1097/JU.0000000000001199

Figure 1.

Figure 1.

Figure 1.

Figure 1.

Discrimination of observed vs. estimated survival based on risk groups in the a) atezolizumab derivation dataset, b) avelumab validation dataset and c) durvalumab validation dataset

Legend: Figures show observed and estimated survival based on low, intermediate and high-risk defined by the derivation dataset. Dashed lines references observed survival in the derivation data.